What is the recommended treatment for cannabis hyperemesis syndrome?

Treatment of Cannabis Hyperemesis Syndrome

Benzodiazepines, specifically lorazepam (0.5–2 mg IV or PO every 4–6 hours), are the most effective first-line acute treatment for cannabis hyperemesis syndrome, with complete cannabis cessation being the only definitive cure requiring at least 6 months of continuous abstinence. 1, 2, 3

Acute Emergency Department Management

First-Line Pharmacotherapy

• Lorazepam is the single most effective agent for acute CHS-related nausea and vomiting, superior to conventional antiemetics based on multiple prospective studies 1, 3, 4
• Administer 0.5–2 mg IV or PO every 4–6 hours during acute episodes 1
• The mechanism combines antiemetic effects through sedation with anxiolytic properties that address the stress-mediated component of CHS 1

Second-Line Pharmacotherapy

• Haloperidol or droperidol are the preferred second-line antipsychotics when benzodiazepines are insufficient 1, 3, 5
• These agents reduce hospital length of stay by approximately 50% (6.7 hours vs 13.9 hours; p=0.014) 1, 3
• Obtain a baseline ECG before administering haloperidol to patients with cardiac risk factors or electrolyte disturbances to identify QT-prolongation risk 1
• Dopamine D₂-receptor antagonism in the chemoreceptor trigger zone, combined with sedating properties, targets both neurochemical and stress-mediated vomiting pathways 1

Adjunctive Therapies

• Topical capsaicin 0.1% cream applied to the abdomen activates TRPV1 receptors and provides consistent symptom relief 1, 2, 3, 6
• Initiate IV fluids containing dextrose for all CHS patients to correct dehydration 1
• Use IV ketorolac as the preferred non-opioid analgesic for severe abdominal pain 1
• Provide a quiet, dimly lit environment to enhance haloperidol's sedating and antiemetic effects 1

Medications to AVOID

• Never use opioids in CHS patients—they exacerbate nausea, carry high addiction risk, and do not address underlying pathophysiology 1, 2, 3, 7, 8
• Ondansetron and other 5-HT₃ antagonists have limited efficacy in CHS and should not be relied upon as primary therapy 1, 2

Diagnostic Confirmation Before Treatment

Rule out life-threatening conditions first: acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction before confirming CHS diagnosis 1, 2

Required Diagnostic Criteria (all three must be present):

• Cannabis exposure: ≥1 year of regular use (>4 times/week) before symptom onset 1, 2, 3
• Clinical pattern: Stereotypical episodic vomiting ≥3 times annually with acute onset 1, 2, 3
• Definitive confirmation: Complete symptom resolution after ≥6 months of continuous cannabis abstinence (or duration equal to 3 typical vomiting cycles) 1, 2, 3

Highly Suggestive Features:

• Compulsive hot-water bathing is reported in 44–71% of CHS cases, though it also occurs in ~44% of cyclic vomiting syndrome patients, limiting diagnostic specificity 1, 3, 8
• Daily or near-daily cannabis use is documented in 68–97% of confirmed cases 1

Definitive Long-Term Management

Cannabis Cessation (The Only Cure)

• Complete and sustained cannabis cessation is the only definitive cure for CHS—partial reduction or switching to edible forms does NOT improve symptoms 1, 2, 3, 8
• Minimum abstinence duration is at least 6 months (or a period equivalent to three typical vomiting cycles for that individual) 1, 2, 3
• Relapse rates exceed 40% in reported series, underscoring the need for ongoing support 1
• Cannabis cessation counseling is mandatory for all CHS patients 1, 2, 3

Preventive Pharmacotherapy

• Tricyclic antidepressants, specifically amitriptyline, are the mainstay of long-term preventive therapy 1, 2, 3, 4
• Dosing protocol: Start at 25 mg at bedtime, increase by 25 mg weekly, targeting a maintenance dose of 75–100 mg at bedtime 1, 2, 3
• Amitriptyline can be initiated even while working toward cannabis cessation 1

Psychosocial Interventions

• Referral to addiction-medicine specialists or substance-use counselors is essential to support sustained abstinence 1, 2, 3
• Co-management with psychiatry is advisable given the high prevalence of anxiety and depression comorbidities 1, 2
• Consider cognitive behavioral therapy or mindfulness meditation to improve overall quality of life 1

Critical Pitfalls to Avoid

• Do NOT pursue extensive diagnostic testing once CHS is suspected—this leads to unnecessary procedures and diagnostic delays averaging several years 1, 2
• Do NOT accept patient denial of the cannabis-symptom link—many patients attribute vomiting to food, alcohol, or stress, which impedes appropriate counseling 1
• Do NOT prescribe haloperidol for outpatient maintenance—reserve it for acute rescue therapy in the ED only 1
• Do NOT over-rely on hot-water bathing as pathognomonic—while present in up to 71% of CHS patients, similar behavior occurs in 44% of cyclic vomiting syndrome cases 1

Distinguishing CHS from Cannabis Withdrawal Syndrome

• CHS occurs DURING active chronic cannabis use (≥4 times/week for >1 year) with vomiting episodes during use 1, 3
• Cannabis Withdrawal Syndrome occurs AFTER cessation, with symptom onset 24–72 hours later, including irritability, anxiety, insomnia, and GI symptoms 1, 3
• This distinction is critical because they require opposite management strategies: CHS requires cessation, while CWS may require supportive care or cannabinoid agonist substitution 1